AIM
AIM ImmunoTech Inc.
There isn't enough reported data to score AIM yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
AIM Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Unavailable | |
| Unavailable |
AIM's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AIM PE Valuation
AIM has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AIM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect AIM's losses to shrink, with revenue declining.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
AIM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$7.79 | +$11.85 |
| Q2 2026 | -$9.10 | +$14.84 |
| Q1 2026 | -$12.24 | +$11.04 |
| Q4 2025 | -$16.40 | +$13.67 |
| Q3 2025 | -$19.64 | +$25.95 |
| Q2 2025 | -$23.94 | +$31.35 |
| Q1 2025 | -$23.28 | +$38.80 |
| Q4 2024 | -$30.07 | +$28.13 |
AIM is still losing money, but far less than before: $7.79 per share over the past year, against $546.07 at its worst in late 2019.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over AIM on earnings quality, reporting a profit while its opponent remains loss making.
AIM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $22K | -15% |
| Q2 2026 | $26K | +4% |
| Q1 2026 | $22K | +38% |
| Q4 2025 | $21K | -53% |
| Q3 2025 | $26K | -26% |
| Q2 2025 | $25K | -50% |
| Q1 2025 | $16K | -60% |
| Q4 2024 | $45K | -31% |
AIM's revenue has slid since its 2023 peak: $22,000 last quarter, down 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -13441% | -4029 points |
| Q2 2026 | -13512% | -2928 points |
| Q1 2026 | -10118% | +12501 points |
| Q4 2025 | -14057% | -1046 points |
| Q3 2025 | -9412% | +3414 points |
| Q2 2025 | -10584% | -3196 points |
| Q1 2025 | -22619% | -8284 points |
| Q4 2024 | -13011% | +8534 points |
AIM's operating margin was −13441% last quarter, down 4029 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AIM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over AIM on profitability, with a higher operating margin.
AIM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4.6M | -$3.1M |
| Q1 2026 | -$2.7M | -$358K |
| Q2 2025 | -$1.5M | +$1.5M |
| Q1 2025 | -$2.4M | +$2.5M |
| Q2 2024 | -$3M | -$850K |
| Q1 2024 | -$4.8M | -$1.1M |
| Q4 2021 | -$5.8M | -$2.9M |
| Q3 2021 | -$3.5M | -$472K |
AIM has burned cash in almost every quarter: −$12M over the past year, against −$14M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
AIM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +90% | +15.4M shares |
| 1 year | +4051% | +31.7M shares |
| 3 years | +6411% | +32M shares |
| 5 years | +8001% | +32.1M shares |
AIM has 32M diluted shares, up 4051% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AIM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AIM Net Leverage
AIM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
AIM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.7 | Oversold |
| Stochastic | 5.5 | Oversold |
AIM's weekly RSI is 29 (oversold) and its Stochastic is 6 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AIM PE vs Healthcare Sector
AIM has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AIM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.17 | 12% below |
| 20 week MA | $0.22 | 32% below |
| 50 week MA | $0.58 | 74% below |
| 100 week MA | $4.33 | 97% below |
| 200 week MA | $22.8 | 99% below |
AIM is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over AIM on trend strength, trading above more of its moving averages.
AIM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $50.8 | $195.0 | +284% |
| 2021 | $195.0 | $103.8 | -47% |
| 2022 | $103.8 | $34.8 | -66% |
| 2023 | $34.8 | $41.4 | +19% |
| 2024 | $41.4 | $19.8 | -52% |
| 2025 | $19.8 | $1.25 | -94% |
| 2026 YTD | $1.25 | $0.15 | -88% |
AIM's yearly returns have swung widely, from +284% in 2020 to −94% in 2025. It's down 88% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AIM on returns for 2026, with the stronger performance.